Literature DB >> 1154557

[Therapy of the carcinoma of the prostate and case control (III) (Author's transl)].

C E Alken, G Dhom, W Straube, J S Braun, B Kopper, H Rehker.   

Abstract

In a third information of our long-term study with now 304 cases we report on 54 cases with monotherapy-only orchiectomy, only hormones and combination of boths. With it the rectal palpable results have coincided significantly with the histological findings in all 3 therapeutic forms. As for the therapeutic result no difference is to be seen either histological or clinical after a 3 years' observation period. We cannot tell anything now about optimal methods of treatment with regard to the histological starting material. In all 3 therapeutic forms we observed regressions to stage O. The smallest plasma-testosteron concentration was found after orchiectomy, where no increase was recorded during the whole observation period.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1154557

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  5 in total

1.  The proliferative pattern of the prostatic carcinoma before and under hormonal treatment.

Authors:  B Helpap; R Stiens; P Brühl
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1976-12-09

Review 2.  Prostatic carcinoma: aspects of pathology, prognosis, and therapy.

Authors:  H Kastendieck
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

3.  Cytological findings in transrectal aspriation biopsy on hormone- and radio-treated carcinoma of the prostate.

Authors:  P Spieler; F Gloor; N Egle; K Bandhauer
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1976-12-07

4.  Cell kinetic and cytological grading of prostatic carcinoma.

Authors:  B Helpap
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

5.  Therapeutic and prognostic aspects of cancer of the prostate detected incidentally in the course of adenoma enucleation.

Authors:  W Leisering
Journal:  Int Urol Nephrol       Date:  1978       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.